Professional Development

Certification

  • EPIC Super User Certificate 2023 (01/2023)

Seminars and Conferences

  • Committee Chair: Hemostasis and Thrombosis Research Society task-force for Coagulopathy in Sickle Cell Disease Chairing the important aspect of Sickle cell disease (SCD). SCD is an inherited gene defect that causes hemoglobin to clump and deform red blood cells, leading to anemia, hemolysis, and vascular occlusions that affect multiple organs. Moreover, sickle shaped red blood cells stick to blood vessel walls thereby slowing or stopping blood flow and the cells lining the blood vessel walls can abnormally express adhesion molecules or proteins that trigger blood coagulation and inflammation in this patients.   (02/2024)
  • American Society of Hematology (Faculty a the National Congress : Committee for ASH-a-Palooza  Blood Drops). (12/2023)
  • Hemostasis and Thrombosis Research Soceity Annual Meeting 2023 National meeting on Bleeding Disorders , where original research on Hemophilia Research was presented.  (04/2023)
  • American Society of Hematology 2022 Annual meeting  (12/2022)
  • International Soceity of Hemostatis & Thrombosis Meeting 2021  (07/2022)
  • American Society of Hematology Annual Meeting 2021  (12/2021)
  • American Academy of Pediatrics Chapter 2 - COVID 19 Coagulopathy and multisystem inflammatory syndrome in children A pediatric hematologist explains multisystem inflammatory syndrome in children and its special relevance in this invited online webinar . (05/2020)

Special Projects

  • Original project’s as Principal Investigator: LLeRA # Principal Investigator   Project Title PT 2180090   Jain, Akshat   (CDA) Bayer HealthCare Pharmaceuticals Inc. / Dr. Akshat Jain PT 2180091   Jain, Akshat   (CDA) Global Blood Therapeutics, Inc. / Dr. Akshat Jain PT 2190027   Jain, Akshat   (CDA) Sanofi / Dr. Akshat Jain PT 2190280   Jain, Akshat   ATLAS-PPX: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in patients with hemophilia A and B previously receiving factor or bypassing agent prophylaxis. PT 2190289   Jain, Akshat   (CDA) Bayer Healthcare Pharmaceuticals / Dr. Akshat Jain PT 2190387   Jain, Akshat   (CDA) Baxalta US, Inc. / Dr. Akshat Jain PT 2190571   Jain, Akshat   ATLAS-INH: A Phase 3 study to evaluate the efficacy and safety of fitsurian in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX PT 2200285   Jain, Akshat   National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 PT 2200406   Jain, Akshat   (CDA) Emory University / Dr. Akshat Jain PT 2200538   Jain, Akshat   (CDA) Dr. Akshat Jain / Octapharma PT 2200565   Jain, Akshat   (CDA) Trio Health / Dr. Akshat Jain PT 2210113   Jain, Akshat   Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Wellebrand Disease Patients Under the Age of 6 Years PT 2210227   Jain, Akshat   An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor) PT 2210231   Jain, Akshat   (CDA) Spark Therapeutics / Dr. Akshat Jain PT 2210258   Jain, Akshat   (CDA) Pfizer, Inc. / Dr. Akshat Jain PT 2210367   Jain, Akshat   ATHN Data Quality Controls / American Thrombosis and Hemostasis Network Affiliation Agreement PT 2220406   Jain, Akshat   (CDA) Bayer Healthcare Pharmaceuticals / Dr. Akshat Jain PREDICT Clinical Study PT 2220452   Jain, Akshat   (CDA) Sanofi US Services / Dr. Akshat Jain PT 2220467   Jain, Akshat   (CDA) Spark Therapeutics / Dr. Akshat Jain PT 2230034   Jain, Akshat   (CDA) CSL Behring, LLC / Dr. Akshat Jain PT 2230035   Jain, Akshat   (CDA) NASCC / Dr. Akshat Jain PT 2230052   Jain, Akshat   Gene and Gene-modified Cell Therapies Medical Education IRB 5200186   Jain, Akshat   University of Alabama at Birmingham: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 IRB 5210168   Jain, Akshat   Clinical study to investigate the efficacy, pharmacokinetics, immunogenicity and safety of Wilate in severe Von Willebrand disease patients under the age of 6 years         Oncology clinical trials and P.I./Co-P.I.   IRB 40303   Children’s Oncology Group   COG-ANBL00B1 Neuroblastoma biology studies Revised 11/30/2000 IRB 5100025   Children’s Oncology Group   COG - ACNS0334: A phase III randomized trial for the treatment of newly diagnosed supratentorial PNET and high risk medulloblastoma in children &lt 36 months old with intensive induction chemotherapy with methotrexate followed by consolidation with stem cell rescue vs. the same therapy without methotrexate IRB 5100187   Children’s Oncology Group   Children's Oncology Group (COG) - ALTE05N1: Umbrella long-term follow-up protocol IRB 5100217   Children’s Oncology Group   Children's Oncology Group (COG)-AALL0932: Treatment of patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy) IRB 5100331   Children’s Oncology Group   Children's Oncology Group (COG) - ACNS0831: Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years IRB 5110017   Children’s Oncology Group   Children's Oncology Group (COG) - AEWS1031: A phase III randomized trial of adding vincristine-topotecan-cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma IRB 5110175   Children’s Oncology Group   COG-AAML1031: A phase III randomized trial for patients with de novo AML using Bortezomib (IND# 58443, NSC#681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for patients with high allelic ratio FLT3/ITD IRB 5110296   Children’s Oncology Group   COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND #73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations IRB 5120126   Children’s Oncology Group   COG-AREN0534: Treatment for patients with bilateral, multicentric, or bilaterally-predisposed unilateral Wilms tumor IRB 5120321   Reeves, Mark E   TSLP and pediatric leukemia mechanisms and treatment IRB 5130167   Children’s Oncology Group   Pediatric blood and marrow transplant consortium (PBMTC) and Canadian Institutes of Health Research (CIHR) - GVHD-1202: Predictive biomarkers for pediatric chronic graft-versus-host disease IRB 5130381   Children’s Oncology Group   COG - ANHL12P1: A randomized phase 2 trial of Brentuximab Vedotin or Crizotinib in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IRB 5140278   Children’s Oncology Group   COG-ANBL 1232:Utilizing response and biology based risk factors to guide therapy in patients with non-high risk neuroblastoma IRB 5140321   Children’s Oncology Group   COG AALL1231: A phase III randomized trial investigating Bortezomib (NSC#681239; IND#58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) IRB 5140416   Children’s Oncology Group   Children's Oncology Group (COG) AALL1331: Risk-stratified randomized phase III testing of blinatumomab (IND#117467, NSC#765986) in first relapse of childhood B-Lymphoblastic Leukemia (B-ALL) IRB 5150002   Children’s Oncology Group   COG AEWS1221: Randomized phase 3 trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab (AMG 479, NSC# 120449) to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma IRB 5150093   Children’s Oncology Group   COG AHOD 1331: randomized phase III study of Brentuximab Vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin Lymphoma (cHL) in children and adolescents IRB 5150354   Children’s Oncology Group   COG AAML1331: A phase III study for patients with newly diagnosed acute promyelocytic Leukemia (APL) using arsenic trioxide and all trans-retinoic acid IRB 5160047   Children’s Oncology Group   COG-APEC14B1: project: EveryChild - a registry, eligibility screening, biology and outcome study IRB 5160052   Children’s Oncology Group   COG A031102: a randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus Ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors IRB 5160061   Children’s Oncology Group   COG AAML1531: Risk-stratified therapy for acute myeloid leukemia in Down Syndrome IRB 5160087   Children’s Oncology Group   COG AOST1421: A phase 2 study of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 (Dinutuximab, NSC #764038, IND #4308) in combination with sargramostim (GM-CSF) in patients with recurrent osteosarcoma IRB 5160300   Children’s Oncology Group   COG ARST1431: A randomized phase 3 study of vincristine, dactinomycin, cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS) IRB 5160357   Children’s Oncology Group   COG AALL 1521 / Incyte INCB 1824-269: A phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with chemotherapy in children with De Novo high-risk CRLF2-rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia IRB 5170232   Children’s Oncology Group   COG AGCT1531: A phase 3 study of active surveillance for low risk and a randomized trial of carboplatin vs. cisplatin for standard risk pediatric and adult patients with germ cell tumors IRB 5170332   Children’s Oncology Group   COG AALL1621: phase 2 study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in children and young adults with relapsed or refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) IRB 5170405   Children’s Oncology Group   COG ACNS1422: A Phase 2 Study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients IRB 5170407   Children’s Oncology Group   COG AALL1631: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones IRB 5180038   Children’s Oncology Group   Nationwide Children's Hospital - Head start IV: Newly diagnosed children (less than 10 years old) with Medulloblastoma and other central nervous system embryonal tumors: Clinical and molecular risk-tailored intensive and compressed induction chemotherapy followed by consolidation with randomization to either single-cycle or to three tandem cycles of marrow-ablative chemotherapy with autologous hematopoietic progenitor cell rescue IRB 5180156   Children’s Oncology Group   COG APEC1621: NCI-COG pediatric MATCH (Molecular Analysis for Therapy Choice) IRB 5180370   Children’s Oncology Group   COG ANBL1531: A Phase 3 study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib added to intensive therapy for children with newly diagnosed high-risk neuroblastoma (NBL) (IND# 134379) IRB 5190014   Children’s Oncology Group   EAP-Oncoceutics-ONC018: Expanded access to ONC201 for patients with H3 K27M-mutant and/or midline high grade gliomas IRB 5190140   Children’s Oncology Group   COG AGCT1532: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors IRB 5190151   Children’s Oncology Group   COG AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) IRB 5190263   Children’s Oncology Group   COG AALL1731: A Phase 3 trial investigating Blinatumomab (IND #117467, NSC #765986) in combination with Chemotherapy in patients with newly diagnosed standard risk or down Syndrome B Lymphoblastic Leukemia (B-ALL) and the treatment of patients with localized B-Lymphoblastic Lymphoma (B-LLy) IRB 5190333   Children’s Oncology Group   COG ADVL1822/ Daiichi Sankyo, Inc. AC220-A-U202: A Phase 1/2, Multicenter, Dose-Escalating study to evaluate the safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib administration in combination with re-induction chemotherapy, and as a single-agent continuation therapy, in pediatric relapsed/refractory AML subjects ages 1 month to &lt18 years (and Young adults ages up to 21 years) with FLT3-ITB mutations IRB 5190358   Abdel-azim, Hisham M.   PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative IRB 5190442   Children’s Oncology Group   COG AALL1732: A phase 3 randomized trial of Inotuzumab Ozogamicin for newly diagnosed high-risk B-ALL; Risk adapted post-induction therapy for high-risk B-ALL, mixed Phenotype acute Leukemia, and Disseminated B-LLy IRB 5200180   Children’s Oncology Group   COG ACNS1723: A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND #145355) IRB 5200225   Children’s Oncology Group   COG ACNS 1831 : A Phase 3 Randomized Study of Selumetinib versus CarboplatiniVincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NFl) associated Low-Grade Glioma (LGG) IRB 5200330   Children’s Oncology Group   COG ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) IRB 5200343   Children’s Oncology Group   COG AMML 1831: A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FL T3 Inhibitor Gilteritinib for Patients with FL T3 Mutations IRB 5200394   Children’s Oncology Group   COG AAML 1921 / ITCC-054: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia IRB 5210087   Chandnani, Harsha Kailash   Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 Infection: An Institutional Experience IRB 5210122   Kheradpour, Albert   SWOG S1826: A Phase 111, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lvmphoma IRB 5210124   Children’s Oncology Group   COG AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged 1-30 Years with First Relapse         Original project’s as Principal Investigator: LLeRA # Principal Investigator   Project Title PT 2180090   Jain, Akshat   (CDA) Bayer HealthCare Pharmaceuticals Inc. / Dr. Akshat Jain PT 2180091   Jain, Akshat   (CDA) Global Blood Therapeutics, Inc. / Dr. Akshat Jain PT 2190027   Jain, Akshat   (CDA) Sanofi / Dr. Akshat Jain PT 2190280   Jain, Akshat   ATLAS-PPX: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in patients with hemophilia A and B previously receiving factor or bypassing agent prophylaxis. PT 2190289   Jain, Akshat   (CDA) Bayer Healthcare Pharmaceuticals / Dr. Akshat Jain PT 2190387   Jain, Akshat   (CDA) Baxalta US, Inc. / Dr. Akshat Jain PT 2190571   Jain, Akshat   ATLAS-INH: A Phase 3 study to evaluate the efficacy and safety of fitsurian in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX PT 2200285   Jain, Akshat   National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 PT 2200406   Jain, Akshat   (CDA) Emory University / Dr. Akshat Jain PT 2200538   Jain, Akshat   (CDA) Dr. Akshat Jain / Octapharma PT 2200565   Jain, Akshat   (CDA) Trio Health / Dr. Akshat Jain PT 2210113   Jain, Akshat   Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Wellebrand Disease Patients Under the Age of 6 Years PT 2210227   Jain, Akshat   An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor) PT 2210231   Jain, Akshat   (CDA) Spark Therapeutics / Dr. Akshat Jain PT 2210258   Jain, Akshat   (CDA) Pfizer, Inc. / Dr. Akshat Jain PT 2210367   Jain, Akshat   ATHN Data Quality Controls / American Thrombosis and Hemostasis Network Affiliation Agreement PT 2220406   Jain, Akshat   (CDA) Bayer Healthcare Pharmaceuticals / Dr. Akshat Jain PREDICT Clinical Study PT 2220452   Jain, Akshat   (CDA) Sanofi US Services / Dr. Akshat Jain PT 2220467   Jain, Akshat   (CDA) Spark Therapeutics / Dr. Akshat Jain PT 2230034   Jain, Akshat   (CDA) CSL Behring, LLC / Dr. Akshat Jain PT 2230035   Jain, Akshat   (CDA) NASCC / Dr. Akshat Jain PT 2230052   Jain, Akshat   Gene and Gene-modified Cell Therapies Medical Education IRB 5200186   Jain, Akshat   University of Alabama at Birmingham: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 IRB 5210168   Jain, Akshat   Clinical study to investigate the efficacy, pharmacokinetics, immunogenicity and safety of Wilate in severe Von Willebrand disease patients under the age of 6 years         Oncology clinical trials and P.I./Co-P.I.   IRB 40303   Children’s Oncology Group   COG-ANBL00B1 Neuroblastoma biology studies Revised 11/30/2000 IRB 5100025   Children’s Oncology Group   COG - ACNS0334: A phase III randomized trial for the treatment of newly diagnosed supratentorial PNET and high risk medulloblastoma in children &lt 36 months old with intensive induction chemotherapy with methotrexate followed by consolidation with stem cell rescue vs. the same therapy without methotrexate IRB 5100187   Children’s Oncology Group   Children's Oncology Group (COG) - ALTE05N1: Umbrella long-term follow-up protocol IRB 5100217   Children’s Oncology Group   Children's Oncology Group (COG)-AALL0932: Treatment of patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy) IRB 5100331   Children’s Oncology Group   Children's Oncology Group (COG) - ACNS0831: Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years IRB 5110017   Children’s Oncology Group   Children's Oncology Group (COG) - AEWS1031: A phase III randomized trial of adding vincristine-topotecan-cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma IRB 5110175   Children’s Oncology Group   COG-AAML1031: A phase III randomized trial for patients with de novo AML using Bortezomib (IND# 58443, NSC#681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for patients with high allelic ratio FLT3/ITD IRB 5110296   Children’s Oncology Group   COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND #73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations IRB 5120126   Children’s Oncology Group   COG-AREN0534: Treatment for patients with bilateral, multicentric, or bilaterally-predisposed unilateral Wilms tumor IRB 5120321   Reeves, Mark E   TSLP and pediatric leukemia mechanisms and treatment IRB 5130167   Children’s Oncology Group   Pediatric blood and marrow transplant consortium (PBMTC) and Canadian Institutes of Health Research (CIHR) - GVHD-1202: Predictive biomarkers for pediatric chronic graft-versus-host disease IRB 5130381   Children’s Oncology Group   COG - ANHL12P1: A randomized phase 2 trial of Brentuximab Vedotin or Crizotinib in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IRB 5140278   Children’s Oncology Group   COG-ANBL 1232:Utilizing response and biology based risk factors to guide therapy in patients with non-high risk neuroblastoma IRB 5140321   Children’s Oncology Group   COG AALL1231: A phase III randomized trial investigating Bortezomib (NSC#681239; IND#58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) IRB 5140416   Children’s Oncology Group   Children's Oncology Group (COG) AALL1331: Risk-stratified randomized phase III testing of blinatumomab (IND#117467, NSC#765986) in first relapse of childhood B-Lymphoblastic Leukemia (B-ALL) IRB 5150002   Children’s Oncology Group   COG AEWS1221: Randomized phase 3 trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab (AMG 479, NSC# 120449) to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma IRB 5150093   Children’s Oncology Group   COG AHOD 1331: randomized phase III study of Brentuximab Vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin Lymphoma (cHL) in children and adolescents IRB 5150354   Children’s Oncology Group   COG AAML1331: A phase III study for patients with newly diagnosed acute promyelocytic Leukemia (APL) using arsenic trioxide and all trans-retinoic acid IRB 5160047   Children’s Oncology Group   COG-APEC14B1: project: EveryChild - a registry, eligibility screening, biology and outcome study IRB 5160052   Children’s Oncology Group   COG A031102: a randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus Ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors IRB 5160061   Children’s Oncology Group   COG AAML1531: Risk-stratified therapy for acute myeloid leukemia in Down Syndrome IRB 5160087   Children’s Oncology Group   COG AOST1421: A phase 2 study of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 (Dinutuximab, NSC #764038, IND #4308) in combination with sargramostim (GM-CSF) in patients with recurrent osteosarcoma IRB 5160300   Children’s Oncology Group   COG ARST1431: A randomized phase 3 study of vincristine, dactinomycin, cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS) IRB 5160357   Children’s Oncology Group   COG AALL 1521 / Incyte INCB 1824-269: A phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with chemotherapy in children with De Novo high-risk CRLF2-rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia IRB 5170232   Children’s Oncology Group   COG AGCT1531: A phase 3 study of active surveillance for low risk and a randomized trial of carboplatin vs. cisplatin for standard risk pediatric and adult patients with germ cell tumors IRB 5170332   Children’s Oncology Group   COG AALL1621: phase 2 study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in children and young adults with relapsed or refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) IRB 5170405   Children’s Oncology Group   COG ACNS1422: A Phase 2 Study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients IRB 5170407   Children’s Oncology Group   COG AALL1631: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones IRB 5180038   Children’s Oncology Group   Nationwide Children's Hospital - Head start IV: Newly diagnosed children (less than 10 years old) with Medulloblastoma and other central nervous system embryonal tumors: Clinical and molecular risk-tailored intensive and compressed induction chemotherapy followed by consolidation with randomization to either single-cycle or to three tandem cycles of marrow-ablative chemotherapy with autologous hematopoietic progenitor cell rescue IRB 5180156   Children’s Oncology Group   COG APEC1621: NCI-COG pediatric MATCH (Molecular Analysis for Therapy Choice) IRB 5180370   Children’s Oncology Group   COG ANBL1531: A Phase 3 study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib added to intensive therapy for children with newly diagnosed high-risk neuroblastoma (NBL) (IND# 134379) IRB 5190014   Children’s Oncology Group   EAP-Oncoceutics-ONC018: Expanded access to ONC201 for patients with H3 K27M-mutant and/or midline high grade gliomas IRB 5190140   Children’s Oncology Group   COG AGCT1532: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors IRB 5190151   Children’s Oncology Group   COG AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) IRB 5190263   Children’s Oncology Group   COG AALL1731: A Phase 3 trial investigating Blinatumomab (IND #117467, NSC #765986) in combination with Chemotherapy in patients with newly diagnosed standard risk or down Syndrome B Lymphoblastic Leukemia (B-ALL) and the treatment of patients with localized B-Lymphoblastic Lymphoma (B-LLy) IRB 5190333   Children’s Oncology Group   COG ADVL1822/ Daiichi Sankyo, Inc. AC220-A-U202: A Phase 1/2, Multicenter, Dose-Escalating study to evaluate the safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib administration in combination with re-induction chemotherapy, and as a single-agent continuation therapy, in pediatric relapsed/refractory AML subjects ages 1 month to &lt18 years (and Young adults ages up to 21 years) with FLT3-ITB mutations IRB 5190358   Abdel-azim, Hisham M.   PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative IRB 5190442   Children’s Oncology Group   COG AALL1732: A phase 3 randomized trial of Inotuzumab Ozogamicin for newly diagnosed high-risk B-ALL; Risk adapted post-induction therapy for high-risk B-ALL, mixed Phenotype acute Leukemia, and Disseminated B-LLy IRB 5200180   Children’s Oncology Group   COG ACNS1723: A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND #145355) IRB 5200225   Children’s Oncology Group   COG ACNS 1831 : A Phase 3 Randomized Study of Selumetinib versus CarboplatiniVincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NFl) associated Low-Grade Glioma (LGG) IRB 5200330   Children’s Oncology Group   COG ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) IRB 5200343   Children’s Oncology Group   COG AMML 1831: A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FL T3 Inhibitor Gilteritinib for Patients with FL T3 Mutations IRB 5200394   Children’s Oncology Group   COG AAML 1921 / ITCC-054: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia IRB 5210087   Chandnani, Harsha Kailash   Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 Infection: An Institutional Experience IRB 5210122   Kheradpour, Albert   SWOG S1826: A Phase 111, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lvmphoma IRB 5210124   Children’s Oncology Group   COG AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged 1-30 Years with First Relapse         (01/2022 - 12/2023)
  • International COVID 19 Sickle Cell Disease Consortium Registry  (06/2020 - Present)